“Clinical development is a three-phase process. During Phase I, small groups of people receive the trial vaccine. In Phase II, the clinical study is expanded and vaccine is given to people who have characteristics (such as age and physical health) similar to those for whom the new vaccine is intended. In Phase III, the vaccine is given to thousands of people and tested for efficacy and safety,” according to the US Center for Disease Control and Prevention (CDC).
“Many vaccines undergo Phase IV formal, ongoing studies after the vaccine is approved and licensed,” CDC added.
Additionally, Kalaycioglu said: “in both studies, the adenoviral vector platform, which is an innovative and effective vaccine development tool, was used to develop a vaccine amid the COVID-19 pandemic. Adenoviral vector platform attracts the attention of researchers due to its potential to stimulate the development of natural, humoral and cellular immune response.”
“This platform only got the European Commission regulatory licensure for the Ebola vaccine on July 1, 2020,” he added.
At least six months protection
Kalaycioglu estimates if everything goes well and a vaccine is developed, it could provide at least six months protection.
He said there are studies which released positive data on early-stage coronavirus vaccine trials such as the Moderna company’s vaccine candidate, “mRNA-1273.”
“In our country, studies on coronavirus vaccine are carried out in prestigious universities. Maybe a safe and effective vaccine will be produced in Turkey,” he said.
01847184424
info@live-technologies.net
Panthapath, Dhaka.
Survey Lancer is a survey and data science company that helps marketers to connect with their customers by letting them know about their customer's needs, wants and demands.
